CATEGORIE

FibroScan® New Generation Extends Access to Non-invasive Liver Diagnosis

domenica 17 aprile 2016

2' di lettura

- Echosens extends its product range with the launch of a new FibroScan® product, the reference liver diagnosis equipment, at EASL 2016 in Barcelona:  FibroScan® 530 Compact.      (Logo: http://photos.prnewswire.com/prnh/20160411/353647LOGO )      (Photo: http://photos.prnewswire.com/prnh/20160411/353648 ) The FibroScan® 530 Compact is designed to increase access to the exclusive FibroScan® VCTE™ (Vibration Controlled Transient Elastography) and CAP™ (Controlled Attenuation Parameter) technologies to monitor fibrosis, cirrhosis and steatosis. As a mobile, easy-to-handle and battery-operated device, FibroScan® 530 Compact extends availability for patients without access to centers with FibroScan® capabilities.   FibroScan® is supported by over 1,300 peer-reviewed publications and is the reference for the AASLD, EASL-ALEH, and WHO guidelines liver disease. FibroScan® products, including the new FibroScan® models, are designed with several quality control systems to support consistency of scan results, irrespective of operator or location. This delivers comparability of results across locations, FibroScan® models, and operators. This consistency provides better information to support patient management, as well as a tool for tracking of results, publishing data and clinical research. Echosens is taking the opportunity to provide ELPA (European Liver Patients Association) with its first FibroScan® 530 Compact at its booth (2200H) during EASL 2016 (the International Liver Congress™) on 14th April at 3:30pm. This mobile device is intended to be used for non-profit liver screening campaigns throughout Europe. About Echosens:  Echosens is an innovative high-technology company based in France. Since its inception in 2001, Echosens has been recognized as the world's leading provider of non-invasive diagnostic devices for chronic liver diseases. The company's innovative, non-invasive technologies are recognized for cost effectively diagnosing and monitoring chronic liver diseases with precision, standardization and repeatability over time and users. The Group owns three products lines: FibroScan®, FibroMeter®, FibroView® which are covered by several families of patents owned by Echosens. Facebook | Twitter | LinkedIn | YouTube For any further information, please contact: Echosens Communication Dpt.communication@echosens.com  Tel: +33-1-44-82-78-50

tag

Ti potrebbero interessare

MILANO CORTINA 2026: LA FIAMMA OLIMPICA PASSA PER SIRACUSA E L’ORTEA PALACE LA CELEBRA CON UNA MOSTRA DI CIMELI DI CORTINA 1956 – ROMA 1960 E TORINO 2006

In occasione del passaggio della fiamma olimpica a Siracusa, previsto per domani, mercoledì 17 dicembre, l’...
Redazione

2WATCH cresce del 60% nel 2025 e punta ai 6 milioni di fatturato nel 2026

2WATCH, leader italiano nel mondo dell’intrattenimento digitale, chiude il 2025 come un anno di svolta: la startup...

Mercosur, Paolo Mascarino (Pres. Federalimentare): “Grazie al Governo successo sulle clausole di salvaguardia. Adesso la UE di fronte ad un bivio, l’Italia può guidarla nella direzione giusta”

“La UE è di fronte ad un bivio: soccombere ai dazi USA e alla spinta espansiva dell’export cinese, op...
Redazione

Assistere con passione, umiltà e professionalità: Entriamo nella casafamiglia “Casangelica” gestita dalla Cooperativa Medihospes

“Lo possiamo dire, la casafamiglia Casangelica, con Medihospes è tra i più virtuosi percorsi di auto...